Capricor Therapeutics (CAPR) Financials

$10.48 +0.23 (+2.24%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$10.52 +0.04 (+0.43%)

As of 05/27/2025 07:56 PM Eastern

Annual Income Statements for Capricor Therapeutics

This table shows Capricor Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-40	-22	-29
Consolidated Net Income / (Loss)	-40	-22	-29
Net Income / (Loss) Continuing Operations	-40	-22	-29
Total Pre-Tax Income	-40	-22	-29
Total Operating Income	-43	-24	-30
Total Gross Profit	22	25	2.55
Total Revenue	22	25	2.55
Operating Revenue	22	25	2.55
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	65	49	32
Selling, General & Admin Expense	15	13	10
Research & Development Expense	50	36	22
Other Special Charges / (Income)	0.11	0.01	0.03
Total Other Income / (Expense), net	2.10	1.79	0.71
Interest & Investment Income	2.20	1.73	0.52
Other Income / (Expense), net	0.01	0.07	0.19
Basic Earnings per Share	($1.15)	($0.83)	($1.18)
Weighted Average Basic Shares Outstanding	35.22M	26.78M	24.55M
Diluted Earnings per Share	($1.15)	($0.83)	($1.18)
Weighted Average Diluted Shares Outstanding	35.22M	26.78M	24.55M
Weighted Average Basic & Diluted Shares Outstanding	45.68M	31.40M	25.26M

This table shows Capricor Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-7.06	-13	-11	-9.79	-0.70	-6.46	-7.37	-7.77	-7.72	-6.37
Consolidated Net Income / (Loss)	-7.12	-13	-11	-9.79	-0.76	-6.39	-7.37	-7.77	-7.72	-6.37
Net Income / (Loss) Continuing Operations	-7.00	-13	-11	-9.79	-0.77	-6.39	-7.37	-7.77	-7.69	-6.37
Total Pre-Tax Income	-7.00	-13	-11	-9.79	-0.77	-6.39	-7.37	-7.77	-7.69	-6.37
Total Operating Income	-7.70	-13	-12	-10	-1.28	-6.86	-7.75	-8.18	-8.07	-6.48
Total Gross Profit	11	2.26	3.97	4.91	12	6.19	3.92	2.99	0.96	1.59
Total Revenue	11	2.26	3.97	4.91	12	6.19	3.92	2.99	0.96	1.59
Operating Revenue	11	2.26	3.97	4.91	12	6.19	3.92	2.99	-	1.59
Total Operating Expenses	19	15	16	15	13	13	12	11	9.06	8.07
Selling, General & Admin Expense	4.27	3.46	3.06	4.07	3.43	3.02	2.85	3.51	2.79	2.56
Research & Development Expense	15	12	13	11	9.94	10	8.82	7.66	6.23	5.50
Total Other Income / (Expense), net	0.58	0.45	0.59	0.47	0.52	0.47	0.38	0.42	0.38	0.11
Interest & Investment Income	0.69	0.45	0.59	0.47	0.45	0.48	0.38	0.42	0.38	0.11
Basic Earnings per Share	($0.11)	($0.38)	($0.35)	($0.31)	$0.02	($0.25)	($0.29)	($0.31)	($0.31)	($0.26)
Weighted Average Basic Shares Outstanding	35.22M	33.09M	31.84M	31.35M	26.78M	25.82M	25.34M	25.25M	24.55M	24.43M
Diluted Earnings per Share	($0.11)	($0.38)	($0.35)	($0.31)	$0.02	($0.25)	($0.29)	($0.31)	($0.31)	($0.26)
Weighted Average Diluted Shares Outstanding	35.22M	33.09M	31.84M	31.35M	26.78M	25.82M	25.34M	25.25M	24.55M	24.43M
Weighted Average Basic & Diluted Shares Outstanding	45.68M	45.47M	32.54M	31.81M	31.40M	30.79M	25.78M	25.27M	25.26M	25.24M

This table details how cash moves in and out of Capricor Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	-3.41	5.09	-25
Net Cash From Operating Activities	-40	-26	4.92
Net Cash From Continuing Operating Activities	-40	-26	4.92
Net Income / (Loss) Continuing Operations	-40	-22	-29
Consolidated Net Income / (Loss)	-40	-22	-29
Depreciation Expense	1.43	1.07	0.53
Non-Cash Adjustments To Reconcile Net Income	9.83	-2.45	4.50
Changes in Operating Assets and Liabilities, net	-11	-1.93	29
Net Cash From Investing Activities	-116	5.11	-35
Net Cash From Continuing Investing Activities	-116	5.11	-35
Purchase of Property, Plant & Equipment	-1.17	-1.31	-2.00
Purchase of Investments	-208	-97	-114
Sale and/or Maturity of Investments	94	105	83
Other Investing Activities, net	-0.37	-0.74	-1.36
Net Cash From Financing Activities	153	26	4.87
Net Cash From Continuing Financing Activities	153	26	4.87
Issuance of Common Equity	152	26	4.80
Other Financing Activities, net	0.45	0.06	0.07
Cash Interest Paid	0.00	0.00	0.00
Cash Income Taxes Paid	0.00	0.00	0.00

This table details how cash moves in and out of Capricor Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-57	58	4.47	-8.48	5.71	-0.85	-0.77	1.00	1.19	-7.98
Net Cash From Operating Activities	-15	-12	-12	-1.27	-12	-8.79	-9.42	4.21	-6.90	-5.69
Net Cash From Continuing Operating Activities	-15	-12	-12	-1.27	-12	-8.79	-9.42	4.21	-6.90	-5.69
Net Income / (Loss) Continuing Operations	-7.12	-13	-11	-9.79	-0.76	-6.39	-7.37	-7.77	-7.72	-6.37
Consolidated Net Income / (Loss)	-7.12	-13	-11	-9.79	-0.76	-6.39	-7.37	-7.77	-7.72	-6.37
Depreciation Expense	0.38	0.36	0.36	0.33	0.31	0.28	0.25	0.23	0.19	0.14
Non-Cash Adjustments To Reconcile Net Income	-7.57	2.00	2.14	13	-7.97	1.72	1.61	2.19	1.18	1.11
Changes in Operating Assets and Liabilities, net	-0.49	-1.45	-3.79	-5.06	-3.17	-4.40	-3.92	9.56	-0.55	-0.56
Net Cash From Investing Activities	-123	2.00	15	-9.50	-5.86	7.72	6.46	-3.21	5.14	-4.18
Net Cash From Continuing Investing Activities	-123	2.00	15	-9.50	-5.86	7.72	6.46	-3.21	5.14	-4.18
Purchase of Property, Plant & Equipment	-0.49	-0.01	-0.06	-0.61	-0.56	-0.27	-0.14	-0.35	-0.69	-0.56
Purchase of Investments	-139	-20	-16	-33	-25	-20	-18	-35	-32	-33
Sale and/or Maturity of Investments	17	22	31	24	20	28	25	32	38	30
Other Investing Activities, net	-0.25	-0.05	-0.02	-0.06	-0.17	-0.36	-0.10	-0.11	-0.53	-0.54
Net Cash From Financing Activities	81	67	2.07	2.29	23	0.22	2.19	0.00	2.95	1.88
Net Cash From Continuing Financing Activities	81	67	2.07	2.29	23	0.22	2.19	0.00	2.95	1.88
Issuance of Common Equity	81	67	1.99	2.29	23	0.22	2.13	0.00	2.92	1.88
Other Financing Activities, net	0.25	0.12	0.08	0.00	0.00	-	0.06	0.00	0.03	0.00

This table presents Capricor Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	170	59	50
Total Current Assets	163	51	43
Cash & Equivalents	11	15	9.60
Short-Term Investments	140	25	32
Prepaid Expenses	1.50	1.00	0.92
Other Current Assets	10	10	0.55
Plant, Property, & Equipment, net	5.56	5.56	4.59
Total Noncurrent Assets	1.53	2.32	2.35
Other Noncurrent Operating Assets	1.53	2.32	2.35
Total Liabilities & Shareholders' Equity	170	59	50
Total Liabilities	25	36	38
Total Current Liabilities	21	31	24
Accounts Payable	8.19	6.25	4.83
Current Deferred Revenue	12	24	18
Other Current Liabilities	0.83	0.75	0.77
Total Noncurrent Liabilities	3.99	4.86	15
Other Noncurrent Operating Liabilities	3.99	4.86	1.88
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	145	23	12
Total Preferred & Common Equity	145	23	12
Preferred Stock	0.00	0.00	0.00
Total Common Equity	145	23	12
Common Stock	344	182	149
Retained Earnings	-200	-159	-137
Accumulated Other Comprehensive Income / (Loss)	1.03	0.24	0.11

This table presents Capricor Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	93	38	49	37	46	54	54
Total Current Assets	86	31	41	30	39	47	48
Cash & Equivalents	68	11	6.21	8.98	9.84	11	8.41
Short-Term Investments	17	19	34	20	28	35	38
Prepaid Expenses	0.39	0.84	1.13	0.46	0.58	0.88	0.34
Other Current Assets	0.41	0.37	0.37	0.55	0.55	0.55	0.55
Plant, Property, & Equipment, net	5.32	5.62	5.89	5.14	4.79	4.81	3.59
Total Noncurrent Assets	1.81	1.99	1.85	2.49	2.03	2.19	2.83
Other Noncurrent Operating Assets	1.81	1.99	1.85	2.49	2.03	2.19	2.83
Total Liabilities & Shareholders' Equity	93	38	49	37	46	54	54
Total Liabilities	25	27	31	39	43	48	39
Total Current Liabilities	20	22	26	33	35	37	23
Accounts Payable	6.53	6.17	6.25	6.77	5.13	5.41	3.94
Current Deferred Revenue	13	15	19	25	29	31	19
Other Current Liabilities	0.81	0.79	0.77	0.75	0.71	0.69	0.70
Total Noncurrent Liabilities	4.21	4.42	4.63	6.01	8.13	11	15
Long-Term Debt	3.38	3.38	3.38	3.38	3.38	3.38	3.38
Other Noncurrent Operating Liabilities	0.83	1.04	1.25	1.68	1.52	1.70	2.08
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	68	12	18	-1.79	2.73	6.21	15
Total Preferred & Common Equity	68	12	18	-1.79	2.73	6.21	15
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	68	12	18	-1.79	2.73	6.21	15
Common Stock	261	192	187	157	155	151	145
Retained Earnings	-193	-180	-169	-159	-152	-145	-129
Accumulated Other Comprehensive Income / (Loss)	0.10	0.15	0.31	0.11	0.18	0.09	0.12

This table displays calculated financial ratios and metrics derived from Capricor Therapeutics' official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	-11.55%	886.81%	941.85%
EBITDA Growth	-79.29%	20.82%	-46.14%
EBIT Growth	-77.25%	18.63%	-47.00%
NOPAT Growth	-76.78%	18.92%	-41.83%
Net Income Growth	-81.57%	23.20%	-44.93%
EPS Growth	-38.55%	29.66%	-35.63%
Operating Cash Flow Growth	-56.25%	-620.61%	129.25%
Free Cash Flow Firm Growth	-53.34%	-573.31%	129.99%
Invested Capital Growth	64.15%	36.34%	-18,707.00%
Revenue Q/Q Growth	-4.12%	79.20%	60.31%
EBITDA Q/Q Growth	-18.23%	23.30%	-5.01%
EBIT Q/Q Growth	-17.73%	22.20%	-5.34%
NOPAT Q/Q Growth	-17.75%	21.98%	-6.02%
Net Income Q/Q Growth	-18.63%	23.79%	-5.57%
EPS Q/Q Growth	-12.75%	28.45%	-4.42%
Operating Cash Flow Q/Q Growth	-8.70%	-22.44%	-20.59%
Free Cash Flow Firm Q/Q Growth	-4.58%	-17.85%	36.53%
Invested Capital Q/Q Growth	54.78%	37.30%	4.62%
Profitability Metrics	-	-	-
Gross Margin	100.00%	100.00%	100.00%
EBITDA Margin	-184.69%	-91.12%	-1,135.57%
Operating Margin	-191.13%	-95.63%	-1,163.93%
EBIT Margin	-191.09%	-95.36%	-1,156.46%
Profit (Net Income) Margin	-181.71%	-88.52%	-1,137.37%
Tax Burden Percent	100.28%	100.00%	100.12%
Interest Burden Percent	94.82%	92.83%	98.23%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%
Return on Equity (ROE)	-48.16%	-129.63%	-134.49%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-37.13%	-44.12%	-64.55%
Return on Assets (ROA)	-35.31%	-40.96%	-63.48%
Return on Common Equity (ROCE)	-48.16%	-129.63%	-134.49%
Return on Equity Simple (ROE_SIMPLE)	-27.82%	-98.61%	-246.22%
Net Operating Profit after Tax (NOPAT)	-30	-17	-21
NOPAT Margin	-133.79%	-66.94%	-814.75%
Net Nonoperating Expense Percent (NNEP)	-11.17%	-13.97%	-23.58%
Return On Investment Capital (ROIC_SIMPLE)	-20.48%	-74.57%	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	66.76%	50.87%	408.86%
R&D to Revenue	224.37%	144.76%	855.07%
Operating Expenses to Revenue	291.63%	195.65%	1,265.28%
Earnings before Interest and Taxes (EBIT)	-43	-24	-30
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-41	-23	-29
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	4.31	6.66	8.27
Price to Tangible Book Value (P/TBV)	4.31	6.66	8.27
Price to Revenue (P/Rev)	28.18	5.98	38.19
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	21.37	4.41	23.28
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	12.08
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	10.61
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.29
Long-Term Debt to Equity	0.00	0.00	0.29
Financial Leverage	-1.14	-2.26	-1.62
Leverage Ratio	1.36	3.16	2.12
Compound Leverage Factor	1.29	2.94	2.08
Debt to Total Capital	0.00%	0.00%	22.27%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	22.27%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	77.73%
Debt to EBITDA	0.00	0.00	-0.12
Net Debt to EBITDA	0.00	0.00	1.31
Long-Term Debt to EBITDA	0.00	0.00	-0.12
Debt to NOPAT	0.00	0.00	-0.16
Net Debt to NOPAT	0.00	0.00	1.83
Long-Term Debt to NOPAT	0.00	0.00	-0.16
Altman Z-Score	13.72	-1.82	-3.74
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	7.77	1.63	1.82
Quick Ratio	7.21	1.26	1.76
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-41	-26	5.60
Operating Cash Flow to CapEx	-3,427.61%	-1,951.46%	245.80%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.19	0.46	0.06
Accounts Receivable Turnover	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	4.00	4.96	0.80
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-
Invested Capital	-6.05	-17	-27
Invested Capital Turnover	-1.94	-1.16	-0.19
Increase / (Decrease) in Invested Capital	11	9.64	-26
Enterprise Value (EV)	476	111	59
Market Capitalization	627	151	97
Book Value per Share	$3.20	$0.73	$0.47
Tangible Book Value per Share	$3.20	$0.73	$0.47
Total Capital	145	23	15
Total Debt	0.00	0.00	3.38
Total Long-Term Debt	0.00	0.00	3.38
Net Debt	-152	-39	-38
Capital Expenditures (CapEx)	1.17	1.31	2.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-9.16	-20	-22
Debt-free Net Working Capital (DFNWC)	142	20	19
Net Working Capital (NWC)	142	20	19
Net Nonoperating Expense (NNE)	11	5.43	8.23
Net Nonoperating Obligations (NNO)	-152	-39	-38
Total Depreciation and Amortization (D&A)	1.43	1.07	0.53
Debt-free, Cash-free Net Working Capital to Revenue	-41.12%	-79.05%	-866.92%
Debt-free Net Working Capital to Revenue	639.23%	77.79%	756.51%
Net Working Capital to Revenue	639.23%	77.79%	756.51%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($1.15)	($0.83)	($1.18)
Adjusted Weighted Average Basic Shares Outstanding	35.22M	26.78M	24.55M
Adjusted Diluted Earnings per Share	($1.15)	($0.83)	($1.18)
Adjusted Weighted Average Diluted Shares Outstanding	35.22M	26.78M	24.55M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	45.68M	31.40M	25.26M
Normalized Net Operating Profit after Tax (NOPAT)	-30	-17	-21
Normalized NOPAT Margin	-133.43%	-66.92%	-813.81%
Pre Tax Income Margin	-181.20%	-88.52%	-1,136.02%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Capricor Therapeutics' official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-7.92%	-63.44%	1.38%	64.29%	1,159.30%	288.66%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	-652.00%	-91.99%	-49.94%	-24.89%	87.64%	-3.90%	-6.74%	-2.79%	-24.98%	-63.31%
EBIT Growth	-500.79%	-89.52%	-49.62%	-25.43%	84.12%	-5.97%	-8.64%	-4.51%	-26.44%	-64.10%
NOPAT Growth	-500.79%	-89.52%	-49.62%	-25.43%	84.12%	-5.97%	-5.81%	-4.51%	-26.44%	-50.14%
Net Income Growth	-833.83%	-96.49%	-49.32%	-26.08%	90.13%	-0.31%	-3.62%	0.64%	-24.72%	-62.04%
EPS Growth	-650.00%	-52.00%	-20.69%	0.00%	106.45%	3.85%	0.00%	3.13%	-19.23%	-52.94%
Operating Cash Flow Growth	-27.62%	-32.38%	-30.48%	-130.13%	-67.98%	-54.69%	-43.95%	-82.49%	-22.65%	-70.33%
Free Cash Flow Firm Growth	-53.93%	-298.59%	-816.52%	-11,883.28%	-150.81%	-129.64%	-114.27%	-101.05%	344.78%	649.18%
Invested Capital Growth	64.15%	50.29%	54.36%	48.66%	36.34%	3.16%	-9.02%	-18.22%	-18,707.00%	-577.78%
Revenue Q/Q Growth	392.14%	-43.05%	-19.06%	-59.41%	95.42%	57.90%	31.16%	211.15%	-39.69%	0.00%
EBITDA Q/Q Growth	42.11%	-12.59%	-13.08%	-920.30%	85.22%	12.07%	5.81%	-1.01%	-24.19%	9.67%
EBIT Q/Q Growth	40.83%	-12.24%	-12.91%	-701.21%	81.33%	11.39%	5.34%	-1.47%	-24.52%	9.16%
NOPAT Q/Q Growth	40.83%	-12.24%	-12.91%	-701.21%	81.33%	11.39%	5.34%	-1.47%	-24.52%	11.53%
Net Income Q/Q Growth	43.32%	-14.15%	-12.31%	-1,185.16%	88.07%	13.25%	5.17%	-0.61%	-21.19%	10.38%
EPS Q/Q Growth	71.05%	-8.57%	-12.90%	-1,650.00%	108.00%	13.79%	6.45%	0.00%	-19.23%	10.34%
Operating Cash Flow Q/Q Growth	-27.09%	5.26%	-868.79%	89.06%	-31.83%	6.61%	-323.70%	161.00%	-21.40%	13.09%
Free Cash Flow Firm Q/Q Growth	28.39%	11.11%	-3.49%	-80.46%	-85.42%	-104.39%	-1,253.09%	-100.99%	8.17%	-1.62%
Invested Capital Q/Q Growth	54.78%	8.20%	20.74%	-33.54%	37.30%	15.71%	10.84%	-35.10%	4.62%	5.12%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-65.78%	-559.27%	-282.88%	-202.46%	-8.05%	-106.50%	-191.26%	-266.33%	-820.37%	-398.40%
Operating Margin	-69.16%	-575.24%	-291.86%	-209.21%	-10.60%	-110.97%	-197.76%	-274.04%	-840.33%	-407.00%
EBIT Margin	-69.16%	-575.24%	-291.86%	-209.21%	-10.60%	-110.97%	-197.76%	-274.04%	-840.33%	-407.00%
Profit (Net Income) Margin	-63.94%	-555.20%	-276.97%	-199.60%	-6.30%	-103.31%	-188.04%	-260.10%	-804.34%	-400.30%
Tax Burden Percent	101.61%	100.00%	100.00%	100.00%	99.30%	100.08%	100.00%	100.00%	100.45%	100.00%
Interest Burden Percent	90.98%	96.52%	94.90%	95.40%	59.90%	93.02%	95.09%	94.91%	95.29%	98.35%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-48.16%	-102.63%	-392.69%	-197.34%	-129.63%	-428.87%	-272.38%	-187.82%	-134.49%	-105.40%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-13.44%	-205.40%	-188.04%	-109.76%	-4.90%	-34.24%	-35.93%	-25.55%	-46.90%	-13.35%
Return on Assets (ROA)	-12.42%	-198.25%	-178.44%	-104.71%	-2.92%	-31.87%	-34.17%	-24.25%	-44.89%	-13.13%
Return on Common Equity (ROCE)	-48.16%	-102.63%	-392.69%	-197.34%	-129.63%	-428.87%	-272.38%	-187.82%	-134.49%	-105.40%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-49.97%	-242.96%	-131.89%	0.00%	1,636.02%	-1,070.13%	-466.78%	0.00%	-178.19%
Net Operating Profit after Tax (NOPAT)	-5.39	-9.11	-8.11	-7.19	-0.90	-4.81	-5.42	-5.73	-5.65	-4.53
NOPAT Margin	-48.41%	-402.67%	-204.31%	-146.45%	-7.42%	-77.68%	-138.43%	-191.83%	-588.23%	-284.90%
Net Nonoperating Expense Percent (NNEP)	-1.81%	-6.46%	-9.50%	-6.61%	0.35%	-4.64%	-4.70%	-4.20%	-5.94%	-4.37%
Return On Investment Capital (ROIC_SIMPLE)	-3.70%	-	-	-	-3.97%	-	-	-	-	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	38.39%	153.15%	77.00%	82.98%	28.37%	48.84%	72.68%	117.52%	291.12%	161.16%
R&D to Revenue	130.77%	522.09%	314.87%	226.23%	82.23%	162.13%	225.08%	256.52%	649.21%	345.85%
Operating Expenses to Revenue	170.17%	675.24%	391.86%	309.21%	110.61%	211.06%	297.76%	374.04%	943.90%	507.00%
Earnings before Interest and Taxes (EBIT)	-7.70	-13	-12	-10	-1.28	-6.86	-7.75	-8.18	-8.07	-6.48
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-7.32	-13	-11	-9.93	-0.97	-6.59	-7.49	-7.95	-7.87	-6.34
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.31	7.25	13.19	11.57	6.66	0.00	44.23	17.17	8.27	9.47
Price to Tangible Book Value (P/TBV)	4.31	7.25	13.19	11.57	6.66	0.00	44.23	17.17	8.27	9.47
Price to Revenue (P/Rev)	28.18	21.31	5.59	7.87	5.98	6.27	12.77	19.24	38.19	91.78
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	21.37	17.79	4.63	6.52	4.41	4.48	9.13	11.70	23.28	64.62
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	12.08	16.61
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	10.61	25.08
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.05	0.29	0.18	0.00	-1.89	1.24	0.54	0.29	0.22
Long-Term Debt to Equity	0.00	0.05	0.29	0.18	0.00	-1.89	1.24	0.54	0.29	0.22
Financial Leverage	-1.14	-1.61	-4.27	-3.20	-2.26	-5.01	-3.85	-3.14	-1.62	-1.61
Leverage Ratio	1.36	1.96	5.92	4.19	3.16	6.68	4.85	3.85	2.12	1.86
Compound Leverage Factor	1.24	1.89	5.62	4.00	1.90	6.21	4.61	3.65	2.02	1.83
Debt to Total Capital	0.00%	4.71%	22.69%	15.48%	0.00%	212.53%	55.28%	35.23%	22.27%	17.96%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	4.71%	22.69%	15.48%	0.00%	212.53%	55.28%	35.23%	22.27%	17.96%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	95.29%	77.31%	84.52%	100.00%	-112.53%	44.72%	64.77%	77.73%	82.04%
Debt to EBITDA	0.00	-0.10	-0.12	-0.14	0.00	-0.11	-0.11	-0.11	-0.12	-0.12
Net Debt to EBITDA	0.00	2.35	0.91	1.46	0.00	0.84	1.16	1.42	1.31	1.57
Long-Term Debt to EBITDA	0.00	-0.10	-0.12	-0.14	0.00	-0.11	-0.11	-0.11	-0.12	-0.12
Debt to NOPAT	0.00	-0.13	-0.16	-0.18	0.00	-0.16	-0.16	-0.16	-0.16	-0.17
Net Debt to NOPAT	0.00	3.23	1.24	2.00	0.00	1.16	1.61	1.99	1.83	2.21
Long-Term Debt to NOPAT	0.00	-0.13	-0.16	-0.18	0.00	-0.16	-0.16	-0.16	-0.16	-0.17
Altman Z-Score	14.39	9.76	-3.22	-0.44	-0.54	-4.96	-3.21	-2.61	-2.32	-0.91
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	7.77	4.19	1.37	1.57	1.63	0.90	1.11	1.25	1.82	2.05
Quick Ratio	7.21	4.15	1.32	1.51	1.26	0.87	1.08	1.22	1.76	2.01
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-16	-23	-25	-25	-11	-5.68	-2.78	-0.21	21	19
Operating Cash Flow to CapEx	-3,027.08%	-127,309.72%	-20,365.43%	-208.42%	-2,075.54%	-3,263.47%	-6,931.29%	1,210.87%	-994.47%	-1,019.61%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.19	0.36	0.64	0.52	0.46	0.31	0.18	0.09	0.06	0.03
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	4.00	4.44	5.22	5.06	4.96	3.22	2.55	1.55	0.80	0.62
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-6.05	-13	-15	-18	-17	-27	-32	-36	-27	-28
Invested Capital Turnover	-1.94	-1.15	-1.17	-1.00	-1.16	-0.51	-0.31	-0.17	-0.19	-0.10
Increase / (Decrease) in Invested Capital	11	14	17	17	9.64	0.88	-2.64	-5.52	-26	-24
Enterprise Value (EV)	476	413	126	177	111	63	86	65	59	103
Market Capitalization	627	495	152	213	151	88	121	107	97	146
Book Value per Share	$3.20	$2.10	$0.36	$0.59	$0.73	($0.07)	$0.11	$0.25	$0.47	$0.63
Tangible Book Value per Share	$3.20	$2.10	$0.36	$0.59	$0.73	($0.07)	$0.11	$0.25	$0.47	$0.63
Total Capital	145	72	15	22	23	1.59	6.11	9.58	15	19
Total Debt	0.00	3.38	3.38	3.38	0.00	3.38	3.38	3.38	3.38	3.38
Total Long-Term Debt	0.00	3.38	3.38	3.38	0.00	3.38	3.38	3.38	3.38	3.38
Net Debt	-152	-82	-26	-37	-39	-25	-34	-42	-38	-43
Capital Expenditures (CapEx)	0.49	0.01	0.06	0.61	0.56	0.27	0.14	0.35	0.69	0.56
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-9.16	-20	-21	-25	-20	-32	-34	-36	-22	-22
Debt-free Net Working Capital (DFNWC)	142	65	8.31	15	20	-3.40	3.77	9.46	19	24
Net Working Capital (NWC)	142	65	8.31	15	20	-3.40	3.77	9.46	19	24
Net Nonoperating Expense (NNE)	1.73	3.45	2.89	2.61	-0.13	1.59	1.94	2.04	2.07	1.84
Net Nonoperating Obligations (NNO)	-152	-82	-26	-37	-39	-25	-35	-42	-38	-43
Total Depreciation and Amortization (D&A)	0.38	0.36	0.36	0.33	0.31	0.28	0.25	0.23	0.19	0.14
Debt-free, Cash-free Net Working Capital to Revenue	-41.12%	-84.73%	-77.89%	-91.85%	-79.05%	-227.19%	-359.81%	-644.79%	-866.92%	-1,401.34%
Debt-free Net Working Capital to Revenue	639.23%	281.33%	30.62%	55.46%	77.79%	-24.19%	39.88%	170.86%	756.51%	1,527.44%
Net Working Capital to Revenue	639.23%	281.33%	30.62%	55.46%	77.79%	-24.19%	39.88%	170.86%	756.51%	1,527.44%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.11)	($0.38)	($0.35)	($0.31)	$0.02	($0.25)	($0.29)	($0.31)	($0.31)	($0.26)
Adjusted Weighted Average Basic Shares Outstanding	35.22M	33.09M	31.84M	31.35M	26.78M	25.82M	25.34M	25.25M	24.55M	24.43M
Adjusted Diluted Earnings per Share	($0.11)	($0.38)	($0.35)	($0.31)	$0.02	($0.25)	($0.29)	($0.31)	($0.31)	($0.26)
Adjusted Weighted Average Diluted Shares Outstanding	35.22M	33.09M	31.84M	31.35M	26.78M	25.82M	25.34M	25.25M	24.55M	24.43M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	45.68M	45.47M	32.54M	31.81M	31.40M	30.79M	25.78M	25.27M	25.26M	25.24M
Normalized Net Operating Profit after Tax (NOPAT)	-5.39	-9.11	-8.11	-7.19	-0.90	-4.80	-5.42	-5.73	-5.65	-4.53
Normalized NOPAT Margin	-48.41%	-402.67%	-204.31%	-146.45%	-7.42%	-77.62%	-138.43%	-191.83%	-588.23%	-284.90%
Pre Tax Income Margin	-62.92%	-555.20%	-276.97%	-199.60%	-6.35%	-103.22%	-188.04%	-260.10%	-800.77%	-400.30%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Capricor Therapeutics' Financials

When does Capricor Therapeutics's fiscal year end?

According to the most recent income statement we have on file, Capricor Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Capricor Therapeutics' net income changed over the last 2 years?

Capricor Therapeutics' net income appears to be on an upward trend, with a most recent value of -$40.47 million in 2024, rising from -$29.02 million in 2022. The previous period was -$22.29 million in 2023. View Capricor Therapeutics' forecast to see where analysts expect Capricor Therapeutics to go next.

What is Capricor Therapeutics's operating income?

Capricor Therapeutics's total operating income in 2024 was -$42.56 million, based on the following breakdown:

Total Gross Profit: $22.27 million
Total Operating Expenses: $64.95 million

How has Capricor Therapeutics revenue changed over the last 2 years?

Over the last 2 years, Capricor Therapeutics' total revenue changed from $2.55 million in 2022 to $22.27 million in 2024, a change of 772.8%.

How much debt does Capricor Therapeutics have?

Capricor Therapeutics' total liabilities were at $25.02 million at the end of 2024, a 30.8% decrease from 2023, and a 34.7% decrease since 2022.

How much cash does Capricor Therapeutics have?

In the past 2 years, Capricor Therapeutics' cash and equivalents has ranged from $9.60 million in 2022 to $14.69 million in 2023, and is currently $11.29 million as of their latest financial filing in 2024.

How has Capricor Therapeutics' book value per share changed over the last 2 years?

Over the last 2 years, Capricor Therapeutics' book value per share changed from 0.47 in 2022 to 3.20 in 2024, a change of 585.2%.

Related Companies

This page (NASDAQ:CAPR) was last updated on 5/28/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Capricor Therapeutics (CAPR) Financials

Frequently Asked Questions About Capricor Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Capricor Therapeutics (CAPR) Financials

Annual Income Statements for Capricor Therapeutics

Quarterly Income Statements for Capricor Therapeutics

Annual Cash Flow Statements for Capricor Therapeutics

Quarterly Cash Flow Statements for Capricor Therapeutics

Annual Balance Sheets for Capricor Therapeutics

Quarterly Balance Sheets for Capricor Therapeutics

Annual Metrics And Ratios for Capricor Therapeutics

Quarterly Metrics And Ratios for Capricor Therapeutics

Frequently Asked Questions About Capricor Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools